EXELIXIS INC. for EXELIXIS INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Proposals related to drug pricing, including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, to include CMMIs GUARD and GLOBE models, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels. Development and implementation of national security policies impacting biotechnology, including regulatory frameworks that may affect cross-border investments, research collaborations, and business operations
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES M. FENTON | — |
| ERIN HERMANCE | — |
| JARED DANIEL MICHAUD | — |
Taxation/Internal Revenue Code TAX
Federal tax policy issues affecting the biopharmaceutical industry, including provisions related to business taxation, research and development incentives, and broader fiscal legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES M. FENTON | — |
| ERIN HERMANCE | — |
| JARED DANIEL MICHAUD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.